RadioRx
Founded Year
2002Stage
Series A - IV | DeadTotal Raised
$20.45MLast Raised
$3.96MAbout RadioRx
RadioRx discovers and develops compounds sourced and adapted from the aerospace industry for treating cancer and other indications. RadioRx’s lead compound is called RRx-001, a structurally unique pharmacophore with novel mechanisms of action (MOA) that are not cross-resistant with approved therapies and that selectively target the microenvironment of the tumor vasculature through a self-amplifying cycle of nitric oxide, free radical, chemokine and cytokine generation under hypoxia. Since RRx-001 increases oxidative stress in tumors, it literally represents a radical approach to cancer treatment.
Loading...
Loading...
RadioRx Patents
RadioRx has filed 6 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/26/2013 | 9/15/2015 | Alkene derivatives, Alkynes, Organic reactions, Ketones, Coupling reactions | Grant |
Application Date | 7/26/2013 |
|---|---|
Grant Date | 9/15/2015 |
Title | |
Related Topics | Alkene derivatives, Alkynes, Organic reactions, Ketones, Coupling reactions |
Status | Grant |
RadioRx Frequently Asked Questions (FAQ)
When was RadioRx founded?
RadioRx was founded in 2002.
Where is RadioRx's headquarters?
RadioRx's headquarters is located at 800 W El Camino Real, Mountain View.
What is RadioRx's latest funding round?
RadioRx's latest funding round is Series A - IV.
How much did RadioRx raise?
RadioRx raised a total of $20.45M.
Who are the investors of RadioRx?
Investors of RadioRx include InterWest Partners.
Loading...
Loading...